Move comes amid company’s shift to focusing on healthcare innovation exclusively.
Johnson & Johnson revealed in a company press release that it will be updating its brand and uniting both its MedTech and pharmaceutical segments under the Johnson & Johnson name. Hoping to concentrate efforts on confronting the toughest health issues and healthcare innovation, the company’s two segments will now be connected to the brand.
According to the organization, Janssen, its pharmaceutical segment, will be renamed Johnson & Johnson Innovative Medicine, and the medical technology segment will continue to be named Johnson & Johnson MedTech.
“Our exclusive focus on Innovative Medicine and MedTech solutions enables us to innovate across the full spectrum of healthcare in ways no other company can,” said Joaquin Duato, board chairman, CEO, Johnson & Johnson. “Uniting our diverse businesses under an updated Johnson & Johnson brand reflects our unique ability to reimagine healthcare through transformative innovation, while staying true to our credo values and the level of care that patients and doctors expect of us.”
Reference: Johnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identity. Business Wire. September 14, 2023. Accessed September 15, 2023. https://www.businesswire.com/news/home/20230914626134/en/Johnson-Johnson-Marks-New-Era-as-Global-Healthcare-Company-With-Updated-Visual-Identity/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.